Medical trial meets one primary endpoint in heart failure with preserved ejection fraction
Sacubitril/valsartan reduces NT-proBNP, a biomarker predictive of long-term clinical outcomes in heart failure, but does not improve functional capacity compared to individualized background therapy in patients with heart ...
Aug 31, 2020
0
4